CAMK2G and type 2 diabetes mellitus: Biguanides and sulphonylureas are widely used in the treatment of T2D, and whilst there is little direct evidence on the effect of these drugs on CaMKII pathways, there is some tangential evidence that they may change the CaMKII signaling pathway.